BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33859753)

  • 1. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 2. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
    He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
    Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.
    Zhang RL; Yang JP; Peng LX; Zheng LS; Xie P; Wang MY; Cao Y; Zhang ZL; Zhou FJ; Qian CN; Bao YX
    Cell Cycle; 2016 Nov; 15(22):3094-3104. PubMed ID: 27767378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
    Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
    Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
    Jiang XL; Zhang Y; Luo CL; Wu XH
    Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
    Long Q; Sun J; Lv J; Liang Y; Li H; Li X
    Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1α in clear cell renal cell carcinoma.
    Zhao P; Deng Y; Wu Y; Guo Q; Zhou L; Yang X; Wang C
    FASEB J; 2021 Feb; 35(2):e21160. PubMed ID: 33150667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC01426 contributes to clear cell renal cell carcinoma progression by modulating CTBP1/miR-423-5p/FOXM1 axis via interacting with IGF2BP1.
    Jiang Y; Zhang H; Li W; Yan Y; Yao X; Gu W
    J Cell Physiol; 2021 Jan; 236(1):427-439. PubMed ID: 32583425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma.
    Zhou W; Yue H; Li C; Chen H; Yuan Y
    Tumour Biol; 2016 Feb; 37(2):2613-9. PubMed ID: 26392112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression analysis of NGAL and NGALR in clear cell renal cell carcinoma.
    Liu F; Li N; Yang W; Wang R; Yu J; Wang X
    Gene; 2018 Nov; 676():269-278. PubMed ID: 30138675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
    Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
    Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
    Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
    Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
    Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
    Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
    Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.
    Song C; Chen T; He L; Ma N; Li JA; Rong YF; Fang Y; Liu M; Xie D; Lou W
    Cell Oncol (Dordr); 2020 Feb; 43(1):51-62. PubMed ID: 31520395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
    Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
    J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.